Clinical Trials Logo

Clinical Trial Summary

This is a double-blind, randomized, placebo-controlled phase I clinical trial with dose-escalation of a synthetic vaccine against Streptococcus pyogenes. The active component of this vaccine candidate is a synthetic polypeptide named StreptInCor designed to elicit humoral and cell-mediated immune responses. The vaccine will be formulated with Aluminium hydroxide in three different doses of StreptInCor (50 µg, 100µg, 200 µg). The proposed vaccination schedule is three doses (0, 1, 6 months). The doses will be escalated for the next group after safety review.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03998592
Study type Interventional
Source Butantan Institute
Contact
Status Withdrawn
Phase Phase 1
Start date May 2021
Completion date October 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02407106 - Efficacy of BLIS K12 as Preventive Measure for Rheumatic Children N/A
Completed NCT03281863 - Clinical Audit on the Managment in Assiut University Children Hospital
Not yet recruiting NCT06259006 - TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children Phase 3
Recruiting NCT04316897 - Prevalence of Rheumatic Heart Disease According to Revised Jones Criteria (2015) in Assiut Governate
Completed NCT04798053 - Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients N/A
Completed NCT02124109 - The Genetic Basis of Acquired Heart Disease in Africa
Recruiting NCT06400628 - Effectiveness of Chronic Self-management Education on Behavioral and Clinical Outcomes N/A